Cerity Partners LLC Increases Stake in argenex SE (NASDAQ:ARGX)

Cerity Partners LLC boosted its stake in argenex SE (NASDAQ:ARGX - Free Report) by 45.3% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,654 shares of the company's stock after purchasing an additional 1,452 shares during the quarter. Cerity Partners LLC's holdings in argenex were worth $2,755,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of ARGX. GeoWealth Management LLC raised its stake in shares of argenex by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after purchasing an additional 18 shares in the last quarter. FIL Ltd bought a new position in shares of argenex during the fourth quarter worth about $38,000. Rakuten Securities Inc. lifted its position in shares of argenex by 56.4% during the first quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock worth $36,000 after purchasing an additional 22 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of argenex during the fourth quarter worth about $38,000. Finally, Huntington National Bank lifted its position in shares of argenex by 1,133.3% during the fourth quarter. Huntington National Bank now owns 74 shares of the company's stock worth $46,000 after purchasing an additional 68 shares during the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ARGX. Baird R W upgraded shares of argenex from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, May 13th. HC Wainwright reiterated a "buy" rating and issued a $720.00 target price on shares of argenex in a research report on Tuesday, July 1st. Oppenheimer increased their target price on shares of argenex from $704.00 to $708.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Deutsche Bank Aktiengesellschaft upgraded shares of argenex from a "hold" rating to a "buy" rating in a research report on Tuesday, July 8th. Finally, Robert W. Baird raised shares of argenex from a "neutral" rating to an "outperform" rating and set a $680.00 price target for the company in a report on Tuesday, May 13th. Nineteen equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $728.06.

argenex Stock Down 1.4%

Shares of NASDAQ:ARGX traded down $8.12 during trading on Friday, reaching $564.59. 336,884 shares of the company traded hands, compared to its average volume of 331,501. The company's 50 day moving average is $563.91 and its two-hundred day moving average is $599.91. The firm has a market capitalization of $34.55 billion, a PE ratio of 34.83, a PEG ratio of 0.98 and a beta of 0.37. argenex SE has a 52 week low of $457.42 and a 52 week high of $678.21.

argenex (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.32 by $0.26. The business had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $748.34 million. argenex had a return on equity of 16.15% and a net margin of 40.20%. As a group, research analysts anticipate that argenex SE will post 3.13 EPS for the current year.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.